Skip to Content
Diagnosed with AS? Biologics can help >

Mitigare (colchicine) Disease Interactions

There are 7 disease interactions with Mitigare (colchicine):

Major

Colchicine (Includes Mitigare) ↔ Bone Marrow Suppression

Severe Potential Hazard, High plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

The use of colchicine should be used with caution in patients with bone marrow suppression. Patients on long term therapy may require periodic blood counts.

References

  1. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW "Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout." J Rheumatol 18 (1991): 264-9
  2. Vedia C, Mascort JJ, Carrasco I, Olive A "Colchicine and thrombopenia." Clin Exp Rheumatol 11 (1993): 458
  3. Finklestein M, Goldman L, Grace ND, Foley M, Randall N "Granulocytopenia complicating colchicine therapy for primary biliary cirrhosis." Gastroenterology 93 (1987): 1231-5
View all 8 references
Major

Colchicine (Includes Mitigare) ↔ Cardiac Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Cardiovascular Disease

The use of colchicine should be used with caution in patients with cardiac dysfunction. The possibility of cumulative effects of colchicine is increased in these patients.

References

  1. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Colchicine (Includes Mitigare) ↔ Dic

Severe Potential Hazard, High plausibility

Applies to: Disseminated Intravascular Coagulation

Colchicine should be used with caution in patients with disseminated intravascular coagulation. Debilitated patients have an increased risk of developing colchicine toxicity.

References

  1. Vedia C, Mascort JJ, Carrasco I, Olive A "Colchicine and thrombopenia." Clin Exp Rheumatol 11 (1993): 458
  2. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Colchicine (Includes Mitigare) ↔ Electrolyte Disturbances

Severe Potential Hazard, High plausibility

Applies to: Hyponatremia, Hypokalemia, Electrolyte Abnormalities

Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting. Therapy with colchicine should be administered with caution in patients with electrolyte imbalances. Monitoring serum electrolytes is recommended in these patients.

References

  1. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
Major

Colchicine (Includes Mitigare) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C). Caution is recommended when prescribing colchicine to these patients.

References

  1. Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L "A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report." J Hepatol 5 (1987): 1-7
  2. Kocak N, Yuce A, Gurakan F, Ozen H, Gogus S, Kale G, Caglar M "Colchicine in the treatment of hepatic fibrosis in children." Am J Gastroenterol 91 (1996): 179-80
  3. Stanley MW, Taurog JD, Snover DC "Fatal colchicine toxicity: report of a case." Clin Exp Rheumatol 2 (1984): 167-71
View all 7 references
Major

Colchicine (Includes Mitigare) ↔ Renal Dysfunction

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction

Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with impaired renal function. Colchicine dosing must be individualized according to the patient's renal function. Caution must be exercised when colchicine therapy is instituted in these patients. Monitoring creatinine function is recommended in patients on long term therapy.

References

  1. "Product Information. Colchicine (colchicine)." Lilly, Eli and Company, Indianapolis, IN.
  2. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW "Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout." J Rheumatol 18 (1991): 264-9
  3. Said R, Hamzeh Y, Tarawneh M, el-Khateeb M, Abdeen M, Shaheen A "Rapid progressive glomerulonephritis in patients with familial Mediterranean fever." Am J Kidney Dis 14 (1989): 412-6
View all 4 references
Moderate

Colchicine (Includes Mitigare) ↔ Rhabdomyolysis

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction, Liver Disease

Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Caution must be exercised when colchicine therapy is instituted in these patients.

Mitigare (colchicine) drug Interactions

There are 378 drug interactions with Mitigare (colchicine)

Mitigare (colchicine) alcohol/food Interactions

There is 1 alcohol/food interaction with Mitigare (colchicine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide